Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company’s progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year. The study is investigating a novel, non-invasive treatment option. Bokhari confirmed that Medicus Pharma has requested a Type C meeting with the US Food and Drug Administ ...